Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells

被引:48
|
作者
He, Xiaocui [1 ,2 ]
Klaesener, Kathrin [1 ,2 ]
Iype, Joseena M. [1 ,3 ]
Becker, Martin [1 ,4 ]
Maity, Palash C. [1 ,3 ]
Cavallari, Marco [1 ]
Nielsen, Peter J. [2 ]
Yang, Jianying [1 ,2 ]
Reth, Michael [1 ,2 ]
机构
[1] Univ Freiburg, Biol 3, BIOSS Ctr Biol Signaling Studies, Fac Biol,Dept Mol Immunol, Freiburg, Germany
[2] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany
[3] Uni Hosp Ulm, Inst Immunol, Ulm, Germany
[4] Helmholtz Zentrum Munchen, Munich, Germany
来源
EMBO JOURNAL | 2018年 / 37卷 / 11期
基金
欧洲研究理事会;
关键词
B-cell antigen receptor; Burkitt lymphoma; Cas9; CRISPR; survival signal; tumor fitness; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; IG-ALPHA; IMMUNE-RESPONSE; BAFF-R; BETA; IMMUNOGLOBULIN; SURVIVAL; PROTEIN; MICE;
D O I
10.15252/embj.201797980
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of the B-cell antigen receptor (BCR) is essential not only for the development but also for the maintenance of mature B cells. Similarly, many B-cell lymphomas, including Burkitt lymphoma (BL), require continuous BCR signaling for their tumor growth. This growth is driven by immunoreceptor tyrosine-based activation motif (ITAM) and PI3 kinase (PI3K) signaling. Here, we employ CRISPR/Cas9 to delete BCR and B-cell co-receptor genes in the human BL cell line Ramos. We find that Ramos B cells require the expression of the BCR signaling component Ig (CD79b), and the co-receptor CD19, for their fitness and competitive growth in culture. Furthermore, we show that in the absence of any other BCR component, Ig can be expressed on the B-cell surface, where it is found in close proximity to CD19 and signals in an ITAM-dependent manner. These data suggest that Ig and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma
    Schrader, Anne M. R.
    Jansen, Patty M.
    Willemze, Rein
    Vermeer, Maarten H.
    Cleton-Jansen, Anne-Marie
    Somers, Sebastiaan F.
    Veelken, Hendrik
    van Eijk, Ronald
    Kraan, Willem
    Kersten, Marie Jose
    van den Brand, Michiel
    Stevens, Wendy B. C.
    de Jong, Daphne
    Hamid, Myrurgia Abdul
    Tanis, Bea C.
    Posthuma, Eduardus F. M.
    Nijland, Marcel
    Diepstra, Arjan
    Pals, Steven T.
    Cleven, Arjen H. G.
    Vermaat, Joost S. P.
    BLOOD, 2018, 131 (18) : 2086 - 2089
  • [32] CD79B EXPRESSION IN DIFFUSE LARGE B CELL LYMPHOMA AS ASSESSED BY FLOW CYTOMETRY OF LYMPH NODE BIOPSIES
    Bellesi, S.
    Maiolo, E.
    Fatone, F.
    Alma, E.
    Iacovelli, C.
    Puggioni, P. L.
    Marchionni, F.
    D'Innocenzo, S.
    Meacci, E.
    Contegiacomo, A.
    Attili, F.
    Larocca, L. M.
    D'Alo, F.
    Hohaus, S.
    HAEMATOLOGICA, 2022, 107 : 78 - 79
  • [33] CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
    Wang, Kemeng
    Wei, Guoqing
    Liu, Delong
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2012, 1
  • [34] CD19 selection improves the sensitivity of B cell lymphoma detection
    Pugh, RE
    Bitter, MA
    Shpall, EJ
    Hami, LS
    Wolf, DM
    Franklin, WA
    JOURNAL OF HEMATOTHERAPY, 1998, 7 (02): : 159 - 168
  • [35] CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
    Kemeng Wang
    Guoqing Wei
    Delong Liu
    Experimental Hematology & Oncology, 1 (1)
  • [36] Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
    Aminov, Sarah
    Giricz, Orsi
    Sica, R. Alejandro
    Polishchuk, Veronika
    Yates, Bonnie
    Wang, Hao-Wei
    Wang, Yanhua
    Sahu, Srabani
    Gordon, Shanisha
    Schinke, Carolina
    Pradhan, Kith
    Aluri, Srinivas
    Janakiram, Murali
    Barta, Stefan K.
    Agarwal, Beamon
    Goldfinger, Mendel
    Shastri, Aditi
    Matsui, William
    Steidl, Ulrich
    Brody, Joshua
    Shah, Nirali N.
    Parekh, Samir
    Verma, Amit
    BLOOD, 2022, 140 : 3480 - 3481
  • [37] Identification, Characterization, and Expression Analysis of CD79A and CD79B in the Sichuan Taimen (Hucho bleekeri)
    Chen, Yeyu
    Yang, Huanchao
    Wu, Xiaoyun
    Liu, Zhao
    Chen, Yanling
    Wei, Qinyao
    Lin, Jue
    Yu, Yi
    Tu, Quanyu
    Li, Hua
    AQUACULTURE RESEARCH, 2025, 2025 (01)
  • [38] Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells
    Cochlovius, B
    Kipriyanov, SM
    Stassar, MJJG
    Christ, O
    Schuhmacher, J
    Strauss, G
    Moldenhauer, G
    Little, M
    JOURNAL OF IMMUNOLOGY, 2000, 165 (02): : 888 - 895
  • [39] CD19 dysregulation in B cells of ANCA vasculitis patients
    Bunch, D. O.
    Khandoobhai, N. B.
    Chin, H.
    Hogan, S. L.
    Clarke, S. H.
    Falk, R. J.
    Nachman, P. H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (01) : S86 - S86
  • [40] Flow cytometry with CD19 gating in the detection of B lymphoma cells infiltrated in the bone marrow
    Kawano, C
    Muroi, K
    Miyazato, A
    Izumi, T
    Hatake, K
    Amemiya, Y
    Ozawa, K
    Miura, Y
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 123 - 123